Global sales of biologic medicines were $87 billion in 2008. Vaccines were back in R&D of major companies (Sanofi Aventis, Glaxo Smith Kline, Merck and Wyeth) with global sales reaching $24 billion because of scare about avian influenza, bioterrorism organisms and new emerging infections like SARS. Introduction of cancer and rotavirus vaccines has greatly expanded the vaccine market. Pravnar® was the second top selling vaccine brand with sales of $ 2.7billion. Gardasil® at $ 2.8 billion was the top vaccine by sales. GSK Hepatitis and Infantrix/Pediatrix Vaccines each with sales of $ 1.2 billion each. Merck, GSK, Sanofi Aventis, Wyeth and Novartis were the top five vaccine companies. More vaccines are likely to reach sales of $ 1 billion and more in the next two years. FDA in 2008 approved 1 new vaccine (Rotarix®)  Several recently launched vaccines like Rotarix® and Menveo® are likely to bring in sales of over $1 billion within 2-3 years of launch. In R&D a follow up Prevanar® from Wyeth looka very attractive. The market and sales data in 2008 provides once again strong support for the R&D paradigm shift to biologic and within biologic towards human monoclonal antibodies, vaccines, erythropoietins, insulin’s and interferons.